Aarti Drugs Limited

AARTIDRUGS

INE767A01016

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2024-04-26 am EDT			5-day change	1st Jan Change
503.8 ^INR	+0.67%		+2.12%	+3.01%

Mar. 29	Aarti Drugs Limited Announces Executive Cessation	CI
Jan. 31	Aarti Drugs Begins Manufacturing Dermatology Products in Tarapur, India Facility	MT

Aarti Drugs Limited Recommends Dividend

July 11, 2019 at 07:39 am EDT

Aarti Drugs Limited recommended a Dividend at 10% i.e. INR 1 per Equity of Face Value of INR 10 each for approval by the shareholders at the upcoming AGM of the Company.

Latest news about Aarti Drugs Limited

Aarti Drugs Limited Announces Executive Cessation	Mar. 29	CI
Aarti Drugs Begins Manufacturing Dermatology Products in Tarapur, India Facility	Jan. 30	MT
Aarti Drugs Limited Initiates Commercial Production of Dermatology Product At New Facility in Tarapur, Maharashtra	Jan. 30	CI
Transcript : Aarti Drugs Limited, Q3 2024 Earnings Call, Jan 25, 2024	Jan. 25
Aarti Drugs Limited Announces Interim Dividend for the Financial Year 2023- 24	Jan. 24	CI
Aarti Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 24	CI
Transcript : Aarti Drugs Limited, Q2 2024 Earnings Call, Oct 20, 2023	23-10-20
Aarti Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-19	CI
Tranche Update on Aarti Drugs Limited's Equity Buyback Plan announced on July 21, 2023.	23-08-28	CI
Aarti Drugs Limited's Equity Buyback announced on July 21, 2023, has closed with 665,000 shares, representing 0.72% for INR 598.5 million.	23-08-16	CI
Aarti Drugs Clocks Gains in Fiscal Q1 Consolidated Profit	23-07-24	MT
Transcript : Aarti Drugs Limited, Q1 2024 Earnings Call, Jul 24, 2023	23-07-24
Aarti Drugs Limited announces an Equity Buyback for 665,000 shares, representing 0.72% for INR 598.5 million.	23-07-21	CI
Aarti Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-21	CI
Aarti Drugs Limited authorizes a Buyback Plan.	23-07-20	CI
Aarti Drugs Limited's Board intends to launch an Equity Buyback on July 21, 2023.	23-07-14	CI
Aarti Drugs Limited's Board intends to launch an Equity Buyback on July 21, 2023.	23-07-14	CI
Transcript : Aarti Drugs Limited, Q4 2023 Earnings Call, May 02, 2023	23-05-02
Aarti Drugs' Consolidated Profit Climbs in Fiscal Q4	23-05-01	MT
Aarti Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-04-29	CI
Transcript : Aarti Drugs Limited, Q3 2023 Earnings Call, Jan 30, 2023	23-01-30
Aarti Drugs' Consolidated Net Profit Declines in Fiscal Q3	23-01-30	MT
Aarti Drugs Limited Declares Interim Dividend for the Financial Year 2022-23	23-01-27	CI
Aarti Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-01-27	CI
Aarti Drugs' Consolidated Profit Falls in Fiscal Q2	22-10-21	MT

Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Aarti Drugs Limited

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

503.8 INR

Average target price

562 INR

Spread / Average Target

+11.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AARTI DRUGS LIMITED	+3.01%	552M
ELI LILLY AND COMPANY	+26.25%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.69%	354B
MERCK & CO., INC.	+20.73%	331B
ABBVIE INC.	+1.97%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.13%	144B

Other Pharmaceuticals